Elizabeth C. Cushman - 27 Jun 2025 Form 3 Insider Report for ABBOTT LABORATORIES (ABT)

Role: EVP, GC AND SECRETARY
Signature: /s/ Elizabeth C. Cushman by Jessica H. Paik, Attorney-in-Fact
Issuer symbol: ABT
Transactions as of: 27 Jun 2025
Net transactions value: $0
Form type: 3
Filing time: 01 Jul 2025, 16:40:37 UTC
Next filing: 26 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Cushman Elizabeth C.	EVP, GC AND SECRETARY	100 ABBOTT PARK ROAD, ABBOTT PARK	/s/ Elizabeth C. Cushman by Jessica H. Paik, Attorney-in-Fact	01 Jul 2025	0002075371

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ABT	Common shares without par value						21,436	27 Jun 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ABT	Option (right to buy)							27 Jun 2025	Common shares	10,439	$106.24	Direct	F1
holding	ABT	Option (right to buy)							27 Jun 2025	Common shares	9,717	$116.98	Direct	F2
holding	ABT	Option (right to buy)							27 Jun 2025	Common shares	20,606	$135.42	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 3,479 on February 17, 2024, 3,480 on February 17, 2025, and 3,480 on February 17, 2026.
F2	Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 3,239 on February 21, 2025, 3,239 on February 21, 2026, and 3,239 on February 21, 2027.
F3	Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,868 on February 25, 2026, 6,869 on February 25, 2027 and 6,869 on February 25, 2028.